Chest ACCP Career Connection
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Glover, J. J.
Right arrow Articles by Morrill, G. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Glover, J. J.
Right arrow Articles by Morrill, G. B.
(Chest. 1995;108:987-990.)
© 1995 American College of Chest Physicians

Conservative Treatment of Overanticoagulated Patients

Jon J. Glover PharmD1 and Gregory B. Morrill PharmD1

1 From the Veterans Affairs Medical Center, and the College of Pharmacy, University of Arizona, Tucson

Study objective: To determine the outcome of overanticoagulated patients who were treated with vitamin K and those who were treated conservatively by holding doses and increasing monitoring frequency. A secondary objective was to compare conservative management with American College of Chest Physicians (ACCP) treatment guidelines when followed.

Design: Retrospective chart review of all patients with international normalized ratios (INRs) of 6 or greater and concurrently receiving warfarin between November 1993 and February 1994.

Setting: A Veterans Affairs Medical Center providing inpatient and outpatient care. Patients receiving warfarin are managed by an established anticoagulation clinic.

Patients: Fifty-one consecutive patients receiving warfarin who had an INR of 6 or greater were reviewed.

Interventions: Data collection included INR, risks for bleeding, indication for anticoagulation, interventions, and patient outcomes.

Results: INRs ranged from 6.1 to 81.8. Forty-eight patients (94%) did not receive vitamin K; they were treated by withholding doses and increasing monitoring frequency. One developed minor bleeding. Three patients (6%) received vitamin K. Two of these patients died of unrelated problems. The third patient required 47 days of heparin therapy prior to achieving therapeutic oral anticoagulation.

Conclusion: This trial showed that conservative treatment of nonbleeding overanticoagulated patients is safe. A prospective trial comparing the ACCP guidelines with a conservative approach is needed.

Key Words: anticoagulants • coumarins • phytonadione • vitamin K • warfarin

Submitted on February 15, 1995
Accepted on May 16, 2007




This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
D. A. Garcia, S. Regan, M. Crowther, and E. M. Hylek
The Risk of Hemorrhage Among Patients With Warfarin-Associated Coagulopathy
J. Am. Coll. Cardiol., February 21, 2006; 47(4): 804 - 808.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
S. E. Wilson, H. G. Watson, and M. A. Crowther
Low-dose oral vitamin K therapy for the management of asymptomatic patients with elevated international normalized ratios: a brief review
Can. Med. Assoc. J., March 2, 2004; 170(5): 821 - 824.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
M. A. Crowther, J. D. Douketis, T. Schnurr, L. Steidl, V. Mera, C. Ultori, A. Venco, and W. Ageno
Oral Vitamin K Lowers the International Normalized Ratio More Rapidly Than Subcutaneous Vitamin K in the Treatment of Warfarin-Associated Coagulopathy: A Randomized, Controlled Trial
Ann Intern Med, August 20, 2002; 137(4): 251 - 254.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
S. E. Wilson, J. D. Douketis, and M. A. Crowther
Treatment of Warfarin-Associated Coagulopathy : A Physician Survey
Chest, December 1, 2001; 120(6): 1972 - 1976.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
J. A. Ginsberg, M. A. Crowther, R. H. White, and T. L. Ortel
Anticoagulation Therapy
Hematology, January 1, 2001; 2001(1): 339 - 357.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
E. M. Hylek, Y. Chang, S. J. Skates, R. A. Hughes, and D. E. Singer
Prospective Study of the Outcomes of Ambulatory Patients With Excessive Warfarin Anticoagulation
Arch Intern Med, June 12, 2000; 160(11): 1612 - 1617.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
G. Raj, R. Kumar, and W. P. McKinney
Time Course of Reversal of Anticoagulant Effect of Warfarin by Intravenous and Subcutaneous Phytonadione
Arch Intern Med, December 13, 1999; 159(22): 2721 - 2724.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
T. R. Lousberg, D. M. Witt, D. G. Beall, B. L. Carter, and D. C. Malone
Evaluation of Excessive Anticoagulation in a Group Model Health Maintenance Organization
Arch Intern Med, March 9, 1998; 158(5): 528 - 534.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. S. Ginsberg
Management of Venous Thromboembolism
N. Engl. J. Med., December 12, 1996; 335(24): 1816 - 1829.
[Full Text] [PDF]

Home page
 JWatch GeneralHome page
IS VITAMIN K NECESSARY FOR OVERANTICOAGULATION?
Journal Watch (General), October 27, 1995; 1995(1027): 2 - 2.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the American College of Chest Physicians.